Abstract
During the last two decades, survival in cases of childhood acute lymphoblastic leukemia (ALL) has improved from 50% to approx 80%. This has been achieved primarily by intensifying therapy, particularly for high-risk groups (1). During this period, biological features of the disease have been investigated for prognostic significance, and along with clinical features, define patient groups for risk-adapted therapy (2). Although the prognostic significance of these variables is dependent on the type and intensity of the treatment regimen, in parallel there have been unprecedented advances made in our understanding of the biology of the disease (3-5).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schrappe, M., Camitta, B., Pui, C. H., et al. (2000) Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia 14, 2193–2194.
Nachman, J. B., Sather, H. N., Sensel, M. G., et al. (1998) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N. Engl. J. Med. 338, 1663–1671.
Jones, L. K. and Saha, V. (2002) Chromatin modification, leukaemia and implications for therapy. Br. J. Haematol. 118, 714–727.
Saha, V., Young, B. D., and Freemont, P. S. (1998) Translocations, fusion genes, and acute leukemia. J. Cell Biochem. 30–31(Suppl.), 264–276.
Look, A. T. (1997) Oncogenic transcription factors in the human acute leukemias. Science 278, 1059–1064.
Secker-Walker, L. M., Swansbury, G. J., and Hardisty, R. M. (1978) Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br. Med. J. 2, 1529–1530.
Look, A. T. (1988) The cytogenetics of childhood leukemia: clinical and biologic implications. Pediatr. Clin. North Am. 35, 723–741.
Golub, T. R., Barker, G. F., Bohlander, S. K., et al. (1995) Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 92, 4917–4921.
Cave, H., Cacheux, V., Raynaud, S., et al. (1997) ETV6 is the target of chromosome 12p deletions in t(12;21) childhood acute lymphocytic leukemia. Leukemia 11, 1459–1464.
Poirel, H., Lacronique, V., Mauchauffe, M., et al. (1998) Analysis of TEL proteins in human leukemias. Oncogene 16, 2895–2903.
Nordgren, A., Heyman, M., Sahlen, S., et al. (2002) Spectral karyotyping and interphase FISH reveal abnormalities not detected by conventional G-banding. Implications for treatment stratification of childhood acute lymphoblastic leukaemia: detailed analysis of 70 cases. Eur. J. Haematol. 68, 31–41.
Harrison, C. J., Gibbons, B., Yang, F., et al. (2000) Multiplex fluorescence in situ hybridization and cross species color banding of a case of chronic myeloid leukemia in blastic crisis with a complex Philadelphia translocation. Cancer Genet. Cytogenet. 116, 105–110.
Lilleyman, J. S. (1998). Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia. Leuk. Lymphoma 31, 501–506.
Szczepanski, T., Orfao, A., van der Velden, V. H., San Miguel, J. F., and van Dongen, J. J. (2001). Minimal residual disease in leukaemia patients. Lancet Oncol. 2, 409–417.
Pallisgaard, N., Clausen, N., Schroder, H., and Hokland, P. (1999). Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer 26, 355–365.
van Dongen, J. J., Macintyre, E. A., Gabert, J. A., et al. (1999). Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13, 1901–1928.
Young, B. D. and Saha, V. (1996). Chromosome abnormalities in leukaemia: the 11q23 paradigm. Cancer Surv. 28, 225–245.
Goulden, N., Oakhill, A., and Steward, C. (2001) Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation. Br. J. Haematol. 112, 275–281.
Szczepanski, T., Willemse, M. J., Brinkhof, B., van Wering, E. R., van der Burg, M., and van Dongen, J. J. (2002) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 99, 2315–2323.
van Dongen, J. J., Seriu, T., Panzer-Grumayer, E. R., et al. (1998). Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352, 1731–1738.
Panzer-Grumayer, E. R., Schneider, M., Panzer, S., Fasching, K., and Gadner, H. (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95, 790–794.
Bader, P., Hancock, J., Kreyenberg, H., et al. (2002) Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. Leukemia 16, 1668–1672.
Knechtli, C. J., Goulden, N. J., Hancock, J. P., et al. (1998) Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92, 4072–1079.
Ginzinger, D. G. (2002) Gene quantification using real-time quantitative PCR: an emerging technology hits the mainstream. Exp. Hematol. 30, 503–512.
Rutherford, A. (2001) Leukemia cells fall on their swords. Trends Mol. Med. 7, 149.
Druker, B. J., Sawyers, C. L., Kantarjian, H., et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038–1042.
Kantarjian, H., Sawyers, C., Hochhaus, A., et al. (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645–652.
Golub, T. R., Slonim, D. K., Tamayo, P., et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286, 531–537.
Yeoh, E. J., Ross, M. E., Shurtleff, S. A., et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1, 133–143.
Ferrando, A. A., Neuberg, D. S., Staunton, J., et al. (2002) Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 1, 75–87.
Velculescu, V. E., Vogelstein, B. & Kinzler, K. W. (2000) Analysing uncharted transcriptomes with SAGE. Trends Genet. 16, 423–425.
Lennard, L., Welch, J. C., and Lilleyman, J. S. (1997) Thiopurine drugs in the treatment of childhood leukaemia: the influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br. J. Clin. Pharmacol. 44, 455–461.
McLeod, H. L., Krynetski, E. Y., Relling, M. V., and Evans, W. E. (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14, 567–572.
Relling, M. V., Yanishevski, Y., Nemec, J., et al. (1998) Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12, 346–352.
Relling, M. V., Rubnitz, J. E., Rivera, G. K., et al. (1999) High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 354, 34–39.
Stanulla, M., Schrappe, M., Brechlin, A. M., Zimmermann, M., and Welte, K. (2000) Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95, 1222–1228.
Ulrich, C. M., Yasui, Y., Storb, R., et al. (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98, 231–234.
Venkatakrishnan, K., von Moltke, L. L., and Greenblatt, D. J. (2000) Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin. Pharmacokinet. 38, 111–180.
Wall, D. B., Kachman, M. T., Gong, S. S., Parus, S. J., Long, M. W., and Lubman, D. M. (2001) Isoelectric focusing nonporous silica reversed-phase high-performance liquid chromatography/electrospray ionization time-of-flight mass spectrometry: a three-dimensional liquid-phase protein separation method as applied to the human erythroleukemia cell-line. Rapid. Commun. Mass Spectrom. 15, 1649–1661.
Wright, G. L., Jr. (2002) SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. Expert Rev. Mol. Diagn. 2, 549–563.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
van Delft, F.W., Saha, V. (2004). Molecular Techniques to Improve Outcome in Childhood ALL. In: Goulden, N.J., Steward, C.G. (eds) Pediatric Hematology. Methods in Molecular Medicine™, vol 91. Humana Press. https://doi.org/10.1385/1-59259-433-6:111
Download citation
DOI: https://doi.org/10.1385/1-59259-433-6:111
Publisher Name: Humana Press
Print ISBN: 978-1-58829-043-4
Online ISBN: 978-1-59259-433-7
eBook Packages: Springer Protocols